Literature DB >> 19029168

Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.

I H Song1, M Rudwaleit, J Listing, J Sieper.   

Abstract

OBJECTIVE: To compare the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with ankylosing spondylitis (AS) without peripheral manifestations.
METHODS: The mini-BASDAI was calculated by omitting questions 3 and 4. The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and tumour necrosis factor alpha inhibitors. Sensitivity to change was assessed by calculating effect sizes.
RESULTS: Up to 70% of AS patients did not have peripheral involvement. Patients with peripheral involvement had higher disease activity in all activity parameters. The mini-BASDAI had higher values compared with the original BASDAI, also in the subgroup with peripheral manifestations. However, the mini-BASDAI did not correlate better with other markers of disease activity compared with the original BASDAI. Furthermore, effect sizes of the original BASDAI and mini-BASDAI were comparable in the treatment trials. Interestingly, approximately 5% of active AS patients with pure axial disease manifestation were identified whose disease activity was underestimated by the original BASDAI.
CONCLUSION: On a group level using the mini-BASDAI did not result in an advantage to assess disease activity or in the subgroup without peripheral involvement. In only approximately 5% of AS patients was the mini-BASDAI superior to the original BASDAI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029168     DOI: 10.1136/ard.2008.099226

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  Comparison of the BASDAI and the miniBASDAI in assessing disease activity in patients with ankylosing spondylitis.

Authors:  Jinane Hakkou; Samira Rostom; Nawal Aissaoui; Kenza Berrada Ghezioul; Rachid Bahiri; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-10-12       Impact factor: 2.980

2.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; U Oberschelp; E Schneider; B Swoboda; H Böhm; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

3.  Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis.

Authors:  Eiman Soliman; W Labib; G el-Tantawi; A Hamimy; A Alhadidy; A Aldawoudy
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

4.  Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Martina Kron; Sonja Kary; Robert Wong; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-03-15       Impact factor: 5.156

5.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 6.  Biologic therapies for spondyloarthritis: what is new?

Authors:  Xenofon Baraliakos; Juergen Braun
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

7.  Predicting the outcome of ankylosing spondylitis therapy.

Authors:  Nathan Vastesaeger; Désirée van der Heijde; Robert D Inman; Yanxin Wang; Atul Deodhar; Benjamin Hsu; Mahboob U Rahman; Ben Dijkmans; Piet Geusens; Bert Vander Cruyssen; Eduardo Collantes; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2011-03-14       Impact factor: 19.103

8.  Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.

Authors:  Maxime Dougados; Emily Wood; Bernard Combe; Thierry Schaeverbeke; Corinne Miceli-Richard; Francis Berenbaum; Nandan Koppiker; Arnaud Dubanchet; Isabelle Logeart
Journal:  Arthritis Res Ther       Date:  2014-11-27       Impact factor: 5.156

9.  Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.

Authors:  Fausto Salaffi; Alessandro Ciapetti; Marina Carotti; Stefania Gasparini; Gustavo Citera; Marwin Gutierrez
Journal:  Health Qual Life Outcomes       Date:  2014-08-22       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.